Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1991 Sep;104(1):195–201. doi: 10.1111/j.1476-5381.1991.tb12407.x

The effects of neuropeptide Y on myocardial contractility and coronary blood flow.

S J Awad 1, R Einstein 1, E K Potter 1, D P Richardson 1
PMCID: PMC1908260  PMID: 1838493

Abstract

1. This study was designed to assess the effects of exogenous neuropeptide Y (NPY) on cardiac contractility and coronary blood flow (CBF) in anaesthetized dogs and to evaluate the effect of NPY on the responses to sympathetic and parasympathetic stimulation and to inotropic agents. 2. Bolus doses of NPY (500 micrograms), administered via the femoral vein, increased mean arterial pressure. The pressor effect was associated with reductions in heart rate, CBF and cardiac contractility. 3. The effects of NPY (500 micrograms) on contractility and CBF were compared with that of vasopressin (VP) (1 unit). For similar reductions in CBF, NPY and VP had similar negative inotropic effects. Thus, it is likely that the negative inotropic response to NPY is not due to a direct effect of NPY on the heart muscle but is largely due to coronary vasoconstriction. 4. In the presence of NPY (500 micrograms, i.v.), there was an inhibition of the positive inotropic response to stimulation of the left cardiac sympathetic nerve (2 or 5 Hz, 0.05 ms). NPY also inhibited the negative inotropic response and chronotropic response to vagal stimulation (2, 3 or 5 Hz, 0.05 ms). 5. Dose-response curves were obtained for the inotropic, chronotropic and pressor responses to cumulative infusions of noradrenaline (n = 6) and dobutamine (n = 6). NPY had no effect on these dose-response curves. 6. The effect of NPY on the responses to salbutamol and impromidine was assessed. NPY did not alter the positive inotropic, chronotropic or depressor responses to these agonists.(ABSTRACT TRUNCATED AT 250 WORDS)

Full text

PDF
195

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aizawa Y., Murata M., Hayashi M., Funazaki T., Ito S., Shibata A. Vasoconstrictor effect of neuropeptide Y (NPY) on canine coronary artery. Jpn Circ J. 1985 Jun;49(6):584–588. doi: 10.1253/jcj.49.584. [DOI] [PubMed] [Google Scholar]
  2. Aizawa Y., Satoh M., Aizawa M., Funazaki T., Niwano S., Miyajima S., Shibata A. Potency and receptors involved in coronary vasoconstriction caused by neuropeptide Y(NPY). Jpn Heart J. 1987 Nov;28(6):891–898. doi: 10.1536/ihj.28.891. [DOI] [PubMed] [Google Scholar]
  3. Allen J. M., Bircham P. M., Edwards A. V., Tatemoto K., Bloom S. R. Neuropeptide Y (NPY) reduces myocardial perfusion and inhibits the force of contraction of the isolated perfused rabbit heart. Regul Pept. 1983 Jul;6(3):247–253. doi: 10.1016/0167-0115(83)90143-x. [DOI] [PubMed] [Google Scholar]
  4. Allen J. M., Gjörstrup P., Björkman J. A., Ek L., Abrahamsson T., Bloom S. R. Studies on cardiac distribution and function of neuropeptide Y. Acta Physiol Scand. 1986 Mar;126(3):405–411. doi: 10.1111/j.1748-1716.1986.tb07834.x. [DOI] [PubMed] [Google Scholar]
  5. Chiba S. Positive chronotropic and negative inotropic actions of vasopressin in isolated blood-perfused canine atrium. Jpn Heart J. 1977 Mar;18(2):221–224. doi: 10.1536/ihj.18.221. [DOI] [PubMed] [Google Scholar]
  6. Clarke J. G., Davies G. J., Kerwin R., Hackett D., Larkin S., Dawbarn D., Lee Y., Bloom S. R., Yacoub M., Maseri A. Coronary artery infusion of neuropeptide Y in patients with angina pectoris. Lancet. 1987 May 9;1(8541):1057–1059. doi: 10.1016/s0140-6736(87)90483-1. [DOI] [PubMed] [Google Scholar]
  7. Courtice G. P., Kwong T. E., Lumbers E. R., Potter E. K. Excitation of the cardiac vagus by vasopressin in mammals. J Physiol. 1984 Sep;354:547–556. doi: 10.1113/jphysiol.1984.sp015392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Edvinsson L., Ekblad E., Håkanson R., Wahlestedt C. Neuropeptide Y potentiates the effect of various vasoconstrictor agents on rabbit blood vessels. Br J Pharmacol. 1984 Oct;83(2):519–525. doi: 10.1111/j.1476-5381.1984.tb16516.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Einstein R., Mihailidou A. S., Richardson D. P. Positive inotropic effects of histamine in anaesthetized dogs. Br J Pharmacol. 1987 Oct;92(2):445–450. doi: 10.1111/j.1476-5381.1987.tb11341.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Goodman A. H., Angus J. A., Einstein R., Cobbin L. B. A device for measuring myocardial contractility. Med Biol Eng. 1972 Jul;10(4):483–495. doi: 10.1007/BF02474196. [DOI] [PubMed] [Google Scholar]
  11. Gu J., Polak J. M., Adrian T. E., Allen J. M., Tatemoto K., Bloom S. R. Neuropeptide tyrosine (NPY)--a major cardiac neuropeptide. Lancet. 1983 May 7;1(8332):1008–1010. doi: 10.1016/s0140-6736(83)92642-9. [DOI] [PubMed] [Google Scholar]
  12. Levy M. N., Ng M. L., Zieske H. Functional distribution of the peripheral cardiac sympathetic pathways. Circ Res. 1966 Sep;19(3):650–661. doi: 10.1161/01.res.19.3.650. [DOI] [PubMed] [Google Scholar]
  13. Lundberg J. M., Hua X. Y., Franco-Cereceda A. Effects of neuropeptide Y (NPY) on mechanical activity and neurotransmission in the heart, vas deferens and urinary bladder of the guinea-pig. Acta Physiol Scand. 1984 Aug;121(4):325–332. doi: 10.1111/j.1748-1716.1984.tb07463.x. [DOI] [PubMed] [Google Scholar]
  14. Lundberg J. M., Stjarne L. Neuropeptide Y (NPY) depresses the secretion of 3H-noradrenaline and the contractile response evoked by field stimulation, in rat vas deferens. Acta Physiol Scand. 1984 Mar;120(3):477–479. doi: 10.1111/j.1748-1716.1984.tb07410.x. [DOI] [PubMed] [Google Scholar]
  15. Lundberg J. M., Tatemoto K. Pancreatic polypeptide family (APP, BPP, NPY and PYY) in relation to sympathetic vasoconstriction resistant to alpha-adrenoceptor blockade. Acta Physiol Scand. 1982 Dec;116(4):393–402. doi: 10.1111/j.1748-1716.1982.tb07157.x. [DOI] [PubMed] [Google Scholar]
  16. Lundberg J. M., Terenius L., Hökfelt T., Martling C. R., Tatemoto K., Mutt V., Polak J., Bloom S., Goldstein M. Neuropeptide Y (NPY)-like immunoreactivity in peripheral noradrenergic neurons and effects of NPY on sympathetic function. Acta Physiol Scand. 1982 Dec;116(4):477–480. doi: 10.1111/j.1748-1716.1982.tb07171.x. [DOI] [PubMed] [Google Scholar]
  17. Mabe Y., Tatemoto K., Huidobro-Toro J. P. Neuropeptide Y-induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine. Eur J Pharmacol. 1985 Oct 8;116(1-2):33–39. doi: 10.1016/0014-2999(85)90182-7. [DOI] [PubMed] [Google Scholar]
  18. Martin S. E., Patterson R. E. Coronary constriction due to neuropeptide Y: alleviation with cyclooxygenase blockers. Am J Physiol. 1989 Sep;257(3 Pt 2):H927–H934. doi: 10.1152/ajpheart.1989.257.3.H927. [DOI] [PubMed] [Google Scholar]
  19. Maturi M. F., Greene R., Speir E., Burrus C., Dorsey L. M., Markle D. R., Maxwell M., Schmidt W., Goldstein S. R., Patterson R. E. Neuropeptide-Y. A peptide found in human coronary arteries constricts primarily small coronary arteries to produce myocardial ischemia in dogs. J Clin Invest. 1989 Apr;83(4):1217–1224. doi: 10.1172/JCI114004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Minson R. B., McRitchie R. J., Chalmers J. P. Effects of neuropeptide Y on left ventricular function in the conscious rabbit. Clin Exp Pharmacol Physiol. 1987 Mar;14(3):263–266. doi: 10.1111/j.1440-1681.1987.tb00387.x. [DOI] [PubMed] [Google Scholar]
  21. Petty M. A., Dietrich R., Lang R. E. The cardiovascular effects of neuropeptide Y (NPY). Clin Exp Hypertens A. 1984;6(10-11):1889–1892. doi: 10.3109/10641968409046098. [DOI] [PubMed] [Google Scholar]
  22. Piper H. M., Millar B. C., McDermott B. J. The negative inotropic effect of neuropeptide Y on the ventricular cardiomyocyte. Naunyn Schmiedebergs Arch Pharmacol. 1989 Sep;340(3):333–337. doi: 10.1007/BF00168519. [DOI] [PubMed] [Google Scholar]
  23. Potter E. K. Neuropeptide Y as an autonomic neurotransmitter. Pharmacol Ther. 1988;37(2):251–273. doi: 10.1016/0163-7258(88)90028-9. [DOI] [PubMed] [Google Scholar]
  24. Potter E. K. Prolonged non-adrenergic inhibition of cardiac vagal action following sympathetic stimulation: neuromodulation by neuropeptide Y? Neurosci Lett. 1985 Mar 15;54(2-3):117–121. doi: 10.1016/s0304-3940(85)80065-3. [DOI] [PubMed] [Google Scholar]
  25. Rioux F., Bachelard H., Martel J. C., St-Pierre S. The vasoconstrictor effect of neuropeptide Y and related peptides in the guinea pig isolated heart. Peptides. 1986 Jan-Feb;7(1):27–31. doi: 10.1016/0196-9781(86)90056-2. [DOI] [PubMed] [Google Scholar]
  26. Rudehill A., Sollevi A., Franco-Cereceda A., Lundberg J. M. Neuropeptide Y (NPY) and the pig heart: release and coronary vasoconstrictor effects. Peptides. 1986 Sep-Oct;7(5):821–826. doi: 10.1016/0196-9781(86)90101-4. [DOI] [PubMed] [Google Scholar]
  27. Tatemoto K., Carlquist M., Mutt V. Neuropeptide Y--a novel brain peptide with structural similarities to peptide YY and pancreatic polypeptide. Nature. 1982 Apr 15;296(5858):659–660. doi: 10.1038/296659a0. [DOI] [PubMed] [Google Scholar]
  28. Tseng C. J., Robertson D., Light R. T., Atkinson J. R., Robertson R. M. Neuropeptide Y is a vasoconstrictor of human coronary arteries. Am J Med Sci. 1988 Jul;296(1):11–16. doi: 10.1097/00000441-198807000-00003. [DOI] [PubMed] [Google Scholar]
  29. Wahlestedt C., Edvinsson L., Ekblad E., Håkanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther. 1985 Sep;234(3):735–741. [PubMed] [Google Scholar]
  30. Wahlestedt C., Wohlfart B., Håkanson R. Effects of neuropeptide Y (NPY) on isolated guinea-pig heart. Acta Physiol Scand. 1987 Apr;129(4):459–463. doi: 10.1111/j.1365-201x.1987.tb10618.x. [DOI] [PubMed] [Google Scholar]
  31. Zukowska-Grojec Z., Marks E. S., Haass M. Neuropeptide Y is a potent vasoconstrictor and a cardiodepressant in rat. Am J Physiol. 1987 Nov;253(5 Pt 2):H1234–H1239. doi: 10.1152/ajpheart.1987.253.5.H1234. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES